About Rui Yi
Rui Yi is a Healthcare company based in Shanghai (China) founded in 2018. Genomics solutions are offered for healthcare and diagnostics. Its Indian entity Realbio Advanced Systems Private Limited reported revenue of ₹1.88 Cr. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Genomics. Its competitors include HitGen, Novogene Corporation and BGI; 2 of its 3 listed competitors have raised funding.
Company details
Rui Yi was founded in 2018 in Shanghai, China, within the biological gene technology and health services sector. High-throughput sequencing and personalized big data analysis solutions are provided to major hospitals and medical centers. Medical services are extended to end customers, while diagnostic techniques for bacteria incubation, livestock management, nutrition, and disease control are developed. Operations focus on genomics applications across healthcare and agricultural domains.
- Headquarters Shanghai, China
- SectorsHealthcare
- Website realbio.com
- Legal Name Realbio Advanced Systems Private Limited
- Date of Incorporation 17 Aug, 2018
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹1.88 Cr
FY 2025 · +18% YoY
- Indian entity net profit₹1.6 Lakh
FY 2025 · 1% margin
- Indian entity EBITDA₹5.6 Lakh
FY 2025 · 3% margin
Associated legal entities of Rui Yi
Rui Yi operates through Realbio Advanced Systems Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Realbio Advanced Systems Private Limited CIN U31909KA2018PTC115557 | Active | 17 Aug 2018 | Bangalore, Karnataka | ₹1.9 Cr | 2 | View details |
Board of directors of Realbio Advanced Systems Private Limited (Rui Yi)
Realbio Advanced Systems Private Limited is the primary company behind Rui Yi. The board of Realbio Advanced Systems Private Limited currently have 2 directors; the longest-serving is Ashvini Nagaraj, appointed in 2018. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ashvini Nagaraj DIN 08201945 | Director | 17 Aug 2018 | 8 yrs 2 mo | Realbio Advanced Systems Private Limited |
| Chetan Maheswarappa DIN 06840004 | Director | 17 Aug 2018 | 8 yrs 2 mo | Realbio Advanced Systems Private Limited |
Financials of Rui Yi
Figures of Realbio Advanced Systems Private Limited, the primary company behind Rui Yi, for FY 2025. Revenue was ₹1.88 Cr (+18% year on year). Net profit was ₹1.6 Lakh (1% margin). EBITDA was ₹5.6 Lakh (3% margin). Revenue has grown at a compounded annual rate of +33% over three years and +5% over five years.
- ₹1.88 CrRevenue · FY 2025 · +18% YoY
- ₹1.6 LakhNet profit · 1% margin
- ₹5.6 LakhEBITDA · 3% margin
- ₹1 LakhPaid-up capital
- +33%Revenue CAGR, 3 years
- +5%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Realbio Advanced Systems Private Limited are on its company page.
Detailed financial statements for Rui Yi
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Rui Yi
Rui Yi has 3 listed competitors in our database, 2 of them funded. They include HitGen, Novogene Corporation and BGI.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hitgen.com | 2012 | Lanzhou, China | $39.11M | DNA-encoded libraries are developed for drug discovery applications. | ||
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| bgi.com | 1999 | Shenzhen, China | 25 | BGI is engaged in genomics and precision medicine solutions. |
Detailed competitors of Rui Yi
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rui Yi
Complete news archive for Rui Yi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rui Yi
Rui Yi was founded in 2018.
Rui Yi is headquartered in Shanghai, China.
The primary company behind Rui Yi, Realbio Advanced Systems Private Limited, reported revenue of ₹1.88 Cr for FY 2025, up 18% year on year.
Rui Yi was founded in 2018 in Shanghai, China, within the biological gene technology and health services sector. High-throughput sequencing and personalized big data analysis solutions are provided to major hospitals and medical centers. Medical services are extended to end customers, while diagnostic techniques for bacteria incubation, livestock management, nutrition, and disease control are developed. Operations focus on genomics applications across healthcare and agricultural domains.
Rui Yi's top competitors include Novogene Corporation, BGI and HitGen.
Rui Yi operates through Realbio Advanced Systems Private Limited.
The legal entities of Rui Yi currently have 2 directors, including Ashvini Nagaraj, Chetan Maheswarappa.